Verdence Capital Advisors LLC Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Verdence Capital Advisors LLC acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,220 shares of the medical equipment provider’s stock, valued at approximately $262,000.

Other institutional investors have also added to or reduced their stakes in the company. Tucker Asset Management LLC grew its position in Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in Lantheus by 97.0% in the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 225 shares during the last quarter. Covestor Ltd boosted its stake in Lantheus by 62.7% in the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock valued at $37,000 after acquiring an additional 203 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in Lantheus by 36.6% in the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 156 shares during the last quarter. Finally, NBC Securities Inc. purchased a new position in Lantheus in the third quarter valued at about $46,000. 99.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on LNTH shares. JMP Securities reiterated a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a research note on Friday, February 23rd. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Truist Financial reiterated a “buy” rating and issued a $82.00 target price (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. Finally, B. Riley boosted their target price on shares of Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $104.71.

Insiders Place Their Bets

In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold 94,545 shares of company stock worth $6,169,936 in the last three months. 2.10% of the stock is currently owned by corporate insiders.

Lantheus Stock Performance

Shares of LNTH stock opened at $64.41 on Wednesday. The stock has a market capitalization of $4.42 billion, a P/E ratio of 13.88 and a beta of 0.53. The company has a current ratio of 5.80, a quick ratio of 5.45 and a debt-to-equity ratio of 0.69. The firm’s 50 day moving average is $60.94 and its 200 day moving average is $62.78. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $100.85.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The business had revenue of $354.00 million for the quarter, compared to analysts’ expectations of $350.44 million. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.